There are currently 54 active clinical trials seeking participants for Glioma research studies. The states with the highest number of trials for Autism participants are California, Pennsylvania, Ohio and Michigan.
Methimazole in Patients With Progressive Glioblastoma
NCT05607407
Recruiting
The purpose of this study is to test the effectiveness, safety, and tolerability of a drug called Methimazole. The investigational drug, Methimazole is not FDA approved for brain tumors, but it is used to treat thyroid illnesses. Different doses of Methimazole will be given to several study participants with glioblastoma. The first several study participants will receive the lowest dose. If the drug does not cause serious side effects, it will be given to other study participants at a higher dos... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Glioblastoma, Glioma
Register for Updates
Resting-State Functional MRI in Glioma Patients Before and After Surgery
NCT03964909
Recruiting
This clinical trial studies how well resting-state functional magnetic resonance imaging (MRI) and cerebrovascular reactivity (CVR) MRI performed before and after surgery works in measuring the effects on language in patients with glioma. Mapping language function before brain tumor resection is crucial for preventing post-surgical deficits and maximizing restoration of language function following surgery. Additional imaging, such as resting-state functional MRI and CVR MRI, may help measure the... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/22/2024
Locations: M D Anderson Cancer Center, Houston, Texas
Conditions: Brain Mass, Glioma
Register for Updates
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
NCT03952598
Recruiting
Background: Glioma is a type of brain cancer. Some of these tumors have gene mutations. These mutations can cause a substance called 2-HG to build up in the brain. This makes the tumors more aggressive. Researchers want to better understand 2-HG buildup in the brain. They hope this can help them design better ways to test for gliomas. Objective: To monitor the level of 2-HG in the brains of people with gliomas that have mutations in the IDH1 or IDH2 genes. Eligibility: People ages 18 and ol... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Glioma, Gliomas, High Grade Glioma, Malignant Glioma, Low Grade Glioma
Register for Updates
Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype
NCT03718767
Recruiting
Background: Gliomas are the most common malignant brain tumors. Some have certain changes (mutations) in the genes IDH1 or IDH2. If there are a high number of mutations in a tumor, it is called hypermutator phenotype (HMP). The drug nivolumab helps the immune system fight cancer. Researchers think it can be more effective in patients with IDH1 or IDH2 mutated gliomas with HMP. They will test gliomas with and without HMP. Objectives: To see if nivolumab stops tumor growth and prolongs the time... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/18/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Glioma, Glioblastoma, High Grage Glioma, Low Grade Glioma, Malignant Glioma
Register for Updates
Tumor Treating Fields for the Treatment of Brainstem Gliomas
NCT05310448
Recruiting
This clinical trial tests the safety and side effects of tumor treating fields in treating patients with gliomas located in the brainstem. Optune is a wearable, portable, treatment that creates low-intensity, wave-like electric fields called tumor treating fields (TTFields), which interfere with cancer cell division. TTFields may prevent growth or decrease size of gliomas in patients
Gender:
All
Ages:
18 years and above
Trial Updated:
04/17/2024
Locations: Emory Proton Therapy Center, Atlanta, Georgia +2 locations
Conditions: Glioma
Register for Updates
Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors
NCT05383872
Recruiting
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/11/2024
Locations: University of California, Los Angeles, Los Angeles, California +13 locations
Conditions: Glioblastoma, Glioma, Liquid Biopsy
Register for Updates
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines (called binimetinib) in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799933... Read More
Gender:
All
Ages:
16 years and above
Trial Updated:
04/10/2024
Locations: Highlands Oncology Group, Fayetteville, Arkansas +41 locations
Conditions: Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
Register for Updates
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
NCT05580562
Recruiting
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.
Gender:
All
Ages:
All
Trial Updated:
04/08/2024
Locations: Barrow Neurological Institute, Phoenix, Arizona +133 locations
Conditions: H3 K27M, Glioma
Register for Updates
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
NCT03796273
Recruiting
This trial studies the side effects and how well ketoconazole works before surgery in treating patients with glioma that has come back or breast cancer that has spread to the brain. Ketoconazole is an antifungal drug that may be able to block a protein, tGLI1 and may help to treat brain tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: Wake Forest University Health Sciences, Winston-Salem, North Carolina
Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Astrocytoma, Breast Carcinoma Metastatic in the Brain, Glioma, Invasive Breast Carcinoma, Oligodendroglioma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Glioma
Register for Updates
A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
NCT05916313
Recruiting
This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful. The purpose of this study is to find out the highest dose of BI 764532 that people with a brain tumour that is positive for DLL3 can tolerate. BI 764532 is an antibody-like molecule that can attach and link together the cancer cells and T-cells of the immune system (DLL3/CD3 bi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/02/2024
Locations: University of California Irvine, Orange, California +3 locations
Conditions: Glioma
Register for Updates
Hyperpolarized Imaging in Diagnosing Participants With Glioma
NCT03739411
Recruiting
This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.
Gender:
All
Ages:
19 years and above
Trial Updated:
03/29/2024
Locations: University of California, San Francisco, San Francisco, California
Conditions: Glioma
Register for Updates
LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
NCT04391595
Recruiting
This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are schedule for resection. In the lead-in cohort, a total of 10 participants will be enrolled into the proposed phase 0 clinical trial. Participants will be administered LY3214996 plus Abemaciclib prior to surgical resection of their tumor. If positive PK results are demonstrated in ≥50% of Phase 0 participants and at least 5 participants are enrolled into Phase 2,... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/25/2024
Locations: Chandler Regional Medical Center, Chandler, Arizona +2 locations
Conditions: Glioblastoma, GBM, Glioma
Register for Updates